Single dose Betalutin® continues to show promising efficacy and safety in recurrent indolent NHL patients
Updated results reported at the International Conference on Malignant Lymphoma (ICML)Oslo, Norway, 14 June 2017 Nordic Nanovector ASA (OSE: NANO) announces that updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with recurrent indolent non-Hodgkin’s lymphoma (iNHL) are being presented at the International Conference on Malignant Lymphoma (ICML) on June 14-17 in Lugano, Switzerland. The LYMRIT 37-01 study is a Phase 1/2 open label, dose escalation study investigating the optimal treatment regimen of single